HOME >> BIOLOGY >> NEWS
Gemcitabine and capecitabine improved overall survival in patients with advanced pancreatic cancer

Paris, France, Wednesday 2 November 2005 - The prognosis of pancreatic cancer is poor but new therapies such as gemcitabine have contributed to improving the outcome for patients. Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients.

Between May 2003 and January 2005, 533 patients with previously untreated or cytological proven locally advanced/metastatic carcinoma of the pancreas were randomised to receive either gemcitabine treatment alone, or gemcitabine and capecitabine treatment. Treatment continued until the disease progressed or the side effects/toxicity effects became intolerable. The primary outcome was survival.

At the time of the interim analysis in May 2005, 70% of deaths had occurred. The median survival for gemcitabine alone and gemcitabine and capecitabine was 6 months and 7.4 months respectively but 1-year survival rates were 19% and 26% respectively. Toxicity effects recorded in both treatment groups included anaemia, neutropenia, thrombocytopenia, fever, diarrhoea and vomiting.

The investigators concluded there was a significant improvement in overall survival by the addition of capecitabine to gemcitabine over gemcitabine alone in advanced pancreatic cancer with acceptable levels of toxicity.

Dr Ian Chau from the Royal Marsden Hospital, UK, commented, The combination of gemcitabine and capecitabine confers a survival advantage over standard gemcitabine monotherapy and may be considered as a new standard of care in advanced pancreatic cancer. Patients will enjoy an improvement in survival with an acceptable level of side effects. This combination could form a new treatment platform to which novel molecular targeted therapy can be added.

About pancreatic cancer
Pancreatic cancer is a very aggressive cancer with an extremely low survival rate. It is very difficult to detect and can be
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
2-Nov-2005


Page: 1 2

Related biology news :

1. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
2. Gene expression pattern could lead to improved treatment of pediatric septic shock
3. Identification of genetic risk factor for coeliac disease promises improved treatment
4. Canadian paper innovation holds promise for improved global health safety
5. Enhanced MR-guided focused ultrasound guidelines demonstrate improved efficacy and durability
6. Toward improved forms of a time-tested cholesterol-fighter
7. Report calls for improved monoclonal antibodies against solid tumors
8. UF scientists test improved gene therapy method for hereditary heart conditions
9. Novel method reveals how menthol discovery could point towards new or improved pain therapies
10. Optimal adjuvant radiation therapy associated with improved survival, meta-analysis shows
11. Calls for improved screening of colorectal cancer in Europes aging population at ECCO 13

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:6/28/2020)... Fla. (PRWEB) , ... June 25, 2020 , ... In ... focus on innovations in accelerated Point of Care Testing solutions (POCT). Check local listings ... Samples are collected at medical offices and are shipped to labs throughout the country. ...
(Date:6/23/2020)... WOODLNDS, Texas (PRWEB) , ... June 23, 2020 ... ... X-ray analytical instrumentation, is pleased to announce the next event in a series ... X-ray scattering. , The TOPIQ series of webinars was developed in response to ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
(Date:7/1/2020)... WESTMINSTER, Colo. (PRWEB) , ... ... ... providers of expert tissue data insights, today announced that the launch of ... PD-L1 results along with data about the tumor microenvironment (TME). , “Flagship’s ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
Breaking Biology Technology:
Cached News: